Hemostatic and fibrinolytic response to nasal desmopressin in hemodialysis patients

Medical Principles and Practice

Volumn 13, Issue 6, 2004, Pages 340-345

  Ulusoy, Sukru ^a   Ovali, Ercument ^a   Aydin, Fazil ^a   Erem, Cihangir ^a   Ozdemir, Feyyaz ^a   Kaynar, Kubra ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Hemodialysis patients; Hemostasis; Nasal desmopressin

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; D DIMER; DESMOPRESSIN; FIBRINOGEN; HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN C; PROTEIN S; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; BLEEDING; BLEEDING TIME; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EUGLOBULIN LYSIS TEST; FEMALE; FIBRINOLYSIS; HEMODIALYSIS; HEMOSTASIS; HUMAN; MALE; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; THROMBOCYTE COUNT;

ADMINISTRATION, INTRANASAL; BLEEDING TIME; BLOOD COAGULATION FACTORS; DEAMINO ARGININE VASOPRESSIN; FEMALE; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; PARTIAL THROMBOPLASTIN TIME; RENAL DIALYSIS;

EID: 5644259514     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080471     Document Type: Article

References (22)

1. Deane FM: Disorders of blood coagulation; in Wyngoarden JB, Smith LH, Bennett JC, Philadelphia WB (eds): Cecil Textbook of Medicine. London, Saunders, 1992, pp 1078-1079.
2. Eberst ME, Berkowitz LR: Homeostasis in renal disease: Pathophysiology and management. Am J Med 1994; 96: 168-179.
3. Lindsay RM, Moorthy AV, Koens F, Linton AL: Platelet function in dialyzed and non-dialyzed patients with chronic renal failure. Clin Nephrol 1975; 4: 52-57.
4. Mannucci PM: Desmopressin: A non-transfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988; 72:1449-1455.
5. Rydzewski A, Rowinski M, Mysliwiec M: Shortening of bleeding time after intranasal administration of 1-deamino-8-D-arginine vasopressin to patients with chronic uremia. Folia Haematol Int Mag Klin Morphol Blutforsch 1986; 113: 823-830.
6. Aunsholt NA, Schmidt EB, Stoffersen E: DDAVP lowers protein C activity in uremics. Nephron 1989; 53: 6-8.
7. Takahashi H, Tatewaki W, Wada K, Niwano H, Hanano M, Shibata A: Plasmin generation and fibrin(ogen)olysis following DDAVP infusion. Am J Hematol 1991; 36: 255-258.
8. Levi M, ten Cate JM, Dooijewaard G, Sturk A, Brommer EJ, Agnelli G: DDAVP induces systemic release of urokinase-type plasminogen activator. Thromb Haemost 1989; 62: 686-689.
9. Woo KT, Wei SS, Lee EJ, Lau YK, Lim CH: Effects of hemodialysis and peritoneal dialysis on antithrombin III and platelets. Nephron 1985; 40: 25-28.
10. Livio M, Benigni A, Remuzzi G: Coagulation abnormalities in uremia. Semin Nephrol 1985;5: 82-90.
11. Remuzzi G, Benigni A, Dodesini P, Schieppati A, Livio M, De Gaetano G, Day SS, Smith WL, Pinca E, Patrignani P, Patrono C: Reduced platelet thromboxane formation in uremia: Evidence for a functional cyclooxygenase defect. J Clin Invest 1983; 71: 762-768.
12. Lazarus JM, Hakim RM: Medical aspects of hemodialysis; in Brenner BM, Rector FC Jr (eds): The Kidney, ed 4. Philadelphia, Saunders, 1991, pp 2248-2249.
13. Charvat J, Konig J, Blaha J: Is heparin responsible for enhanced platelet aggregation after hemodialysis? Nephron 1986; 44: 89-91.
14. Joseph WB, Rector FC Jr (eds): The Kidney, ed 4. Philadelphia, Saunders, 1991, pp 2027-2029.
15. Remuzzi G, Pusineri F: Coagulation defect in uremia. Kidney Int 1988; 33(suppl 24):S13-S17.
16. Di Minno G, Martinez J, McKean ML, De La Rosa J, Burke JF, Murphy S: Platelet dysfunction in uremia: Multifaceted defect partially corrected by dialysis. Am J Med 1985; 79: 552-559.
17. Bockenstedt P, Greenberg JM, Handin RI: Structural basis of von Willebrand factor binding to platelet glycoprotein Ib and collagen: Effects of disulfide reduction and limited proteolysis of polymeric von Willebrand factor. J Clin Invest 1986; 77: 743-749.
18. Parker RI, Gralnick HR: Identification of platelet glycoprotein IIb-IIIa as the major binding site for released platelet von Willebrand factor. Blood 1986; 68: 732-736.
19. Horstman LL, Valle Riestra BJ, Jy W, Wang F, Mao W, Ahn YS: DDAVP acts on platelets to generate platelet microparticles and enhanced procoagulant activity. Thromb Res 1995; 79: 163-174.
20. Chen KS, Huang CC, Leu ML, Deng P, Lo SK: Hemostatic and fibrinolytic response to desmopressin in uremic patients. Blood Purif 1997; 15: 84-91.
21. Couch P, Stumpf JL: Management of uremic bleeding. Clin Pharm 1990; 9: 673-681.
22. Malyszko J, Pietraszek MH, Azzadin A, Buczko W, Mysliwiec M: DDAVP induces decrease in platelet serotonin content in uremia. Thromb Haemost 1989; 30: 537-537.